Paid Clinical Trials in Pennsylvania

Pennsylvania has 3,479 paid clinical trials enrolling now across cities including Philadelphia, Pittsburgh and Hershey. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Research sites in Pennsylvania include Penn Medicine, Children's Hospital of Philadelphia and UPMC, running studies across oncology, cardiology, neurology, and more. Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 4, 2026.

Filter results

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

3,012 clinical trials

Get a weekly email when new trials open in Philadelphia, PA.

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

for Proteinuric Kidney Diseases

Sites in Bethlehem +25 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 12+

Code: NCT07355296·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

for Obesity

Drug: Eloralintide

Sites in Uniontown +40 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07321886·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

for Non-Small Cell Lung Cancer (NSCLC)

Drug: Pumitamig

Sites in Pittsburgh, York +39 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07361510·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

for Schizophrenia

Drug: KarXT

Sites in Philadelphia, State College +53 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07379827·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

for Clostridoides Difficile Associated Disease

Sites in Philadelphia, Camp Hill +138 more locations

Sponsor: Pfizer

Sex: All·Age: 65+·Accepts healthy volunteers

Code: NCT07282665·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

for Ventricular Arrythmia

Sites in Philadelphia, Hershey +25 more locations

Sponsor: AtaCor Medical, Inc.

Sex: All·Age: 18+

Code: NCT07324031·Recruiting·Listed Jan 2026

Apply to this trial

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

for Overweight

Drug: Eloralintide

Sites in Pittsburgh, Uniontown +58 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07282600·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

for Parkinson's Disease

Sites in Philadelphia +25 more locations

Sponsor: Bayer

Sex: All·Age: 45 - 75

Code: NCT07330258·Recruiting·Listed Jan 2026

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

for CRC (Colorectal Cancer)

Drug: Bevacizumab

Sites in Philadelphia, Pittsburgh +69 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07284849·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

for Diabetic Kidney Disease (DKD)

Sites in Bethlehem, West Chester +56 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18 - 80

Code: NCT07271186·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

for Squamous Cell Carcinoma of Head and Neck

Drug: Amivantamab

Sites in Hershey +46 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07276399·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

for Type 2 Diabetes

Sites in West Chester +59 more locations

Sponsor: Sparrow Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07296484·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

for Atopic Dermatitis

Sites in Pittsburgh +45 more locations

Sponsor: Sanofi

Sex: All·Age: 12+

Code: NCT07290803·Recruiting·Listed Dec 2025

Apply to this trial

Study of DONQ52 in Active Celiac Disease

for Celiac Disease

Drug: DONQ52

Sites in Harrisburg +57 more locations

Sponsor: Chugai Pharmaceutical

Sex: All·Age: 18 - 75

Code: NCT07239336·Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

for Overweight

Sites in Pittsburgh +33 more locations

Sponsor: Novo Nordisk A/S

Sex: All·Age: 8 - 18

Code: NCT07253285·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

for Diabetic Peripheral Neuropathic Pain

Drug: LY4065967

Sites in Duncansville +35 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07285018·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

for Prostatic Neoplasms, Castration-Resistant

Drug: Pasritamig

Sites in Pittsburgh, Hershey +51 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07225946·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for Non-small Cell Carcinoma

Sites in Wynnewood, Media +216 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study of Buntanetap in Participants With PD

for Parkinson's Disease (PD)

Sites in Willow Grove +26 more locations

Sponsor: Annovis Bio Inc.

Sex: All·Age: 40 - 85

Code: NCT07284784·Phase 2, Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

for Untreated, Unresectable, or Metastatic Colorectal Cancer

Drug: Bevacizumab

Sites in Pittsburgh, Allentown +42 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221357·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

for Metabolic Dysfunction-Associated Steatotic Liver Disease

Sites in Philadelphia, Wyomissing +140 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07165028·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Sites in Philadelphia +38 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07258511·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Drug: Nivolumab

Sites in Pittsburgh +33 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221149·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for Carcinoma, Transitional Cell

Sites in Pittsburgh, Lancaster +62 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

for Focal Segmental Glomerulosclerosis

Sites in Philadelphia, Bethlehem +71 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 12+

Code: NCT07220083·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

for Hidradenitis Suppurativa (HS)

Sites in Pittsburgh +30 more locations

Sponsor: Bluefin Biomedicine, Inc.

Sex: All·Age: 18 - 75

Code: NCT07287644·Phase 2, Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

for Peripheral Arterial Disease

Drug: Orforglipron

Sites in Camp Hill +34 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07223593·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Brenipatide in Participants With Alcohol Use Disorder

for Alcohol Use Disorder

Drug: Brenipatide

Sites in Philadelphia +28 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18 - 75

Code: NCT07219953·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

Sites in Pittsburgh +42 more locations

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT07213674·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

for Alcohol Use Disorder

Drug: Brenipatide

Sites in Philadelphia +29 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18 - 75

Code: NCT07219966·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

Sites in Philadelphia, Bethlehem +123 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

for Elevated Lp(a)

Drug: Muvalaplin

Sites in Philadelphia, Allentown +153 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07157774·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

for Diabetes Mellitus, Type 2

Drug: Empagliflozin

Sites in Philadelphia, Pittsburgh +202 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07064473·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

for Ulcerative Colitis

Drug: Duvakitug

Sites in Philadelphia, Pittsburgh +116 more locations

Sponsor: Sanofi

Sex: All·Age: 16 - 80

Code: NCT07184996·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

for Alzheimers Disease

Sites in Plymouth Meeting +67 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 90

Code: NCT07177352·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

for Dystonia

Sites in Philadelphia +36 more locations

Sponsor: Vima Therapeutics

Sex: All·Age: 18 - 65

Code: NCT07304089·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

for Cardiovascular Disease

Drug: Olpasiran

Sites in Philadelphia, Pittsburgh +192 more locations

Sponsor: Amgen

Sex: All·Age: 50 - 105

Code: NCT07136012·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

Sites in Philadelphia, Willow Grove +86 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

for Breast Neoplasms

Sites in Pittsburgh +48 more locations

Sponsor: Natera, Inc.

Sex: All·Age: 18+

Code: NCT07214532·Recruiting·Listed Oct 2025

Apply to this trial

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

for Healthy

Sites in Pittsburgh +117 more locations

Sponsor: Pfizer

Sex: All·Age: 1 Day - 49·Accepts healthy volunteers

Code: NCT07160244·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial